F-star Therapeutics, Inc. (FSTX) Research

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.

Market snapshot

Symbol
FSTX
Price
$7.12
Day change
0.00%
Market cap
$156.5M
P/E ratio
-3.79x
52-week range
2.07-7.12
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • aTyr Pharma, Inc. (ATYR)
  • Decibel Therapeutics, Inc. (DBTX)
  • eXoZymes, Inc. (EXOZ)
  • NGM Biopharmaceuticals, Inc. (NGM)
  • Pardes Biosciences, Inc. (PRDS)
  • Paratek Pharmaceuticals, Inc. (PRTK)
  • Selecta Biosciences, Inc. (SELB)
  • Sesen Bio, Inc. (SESN)

Recent insider activity

  • Kayitalire Louis — U-Tender (29236 shares) on 2023-03-08
  • Kayitalire Louis — D-Return (25019 shares) on 2023-03-08
  • Kayitalire Louis — D-Return (27289 shares) on 2023-03-08
  • Kayitalire Louis — D-Return (35719 shares) on 2023-03-08
  • Kayitalire Louis — D-Return (53634 shares) on 2023-03-08

Open F-star Therapeutics, Inc. (FSTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.